Ketan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.
Ketan K. Badani, MD, vice chairman of Urology and Robotic Operations for the Mount Sinai Health System and director of Robotic Surgery for Mount Sinai, Mount Sinai St. Luke’s, and Mount Sinai Roosevelt Hospitals, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma (RCC).
There are a few trials looking at immuno-oncology agents such as nivolumab (Opdivo). One trial called PROSPER investigated neoadjuvant therapy with nivolumab before surgery for patients with higher risk tumors. Badani says another trial is looking at ipilimumab (Yervoy) and nivolumab together before cytoreductive nephrectomy.
These drugs are being used in place of tyrosine kinase inhibitors such as sunitinib (Sutent) and sorafenib (Nexavar), which are now older treatments in the RCC setting. Now there are many second- and third-line agents that need to be looked at in the same setting. Badani thinks if investigators look at cytoreductive nephrectomy with immune-oncology agents and VEGF agents, there may be completely different results, and even benefit, for higher-risk patients. He hopes that the accrual for these trials is high, since these regimens are usually well-tolerated.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More